A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis

Summary

To investigate the safety and tolerability of repeated subcutaneous (s.c.) doses of MOR106 administered concomitantly with topical corticosteroids (TCS) in participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

Timeline

Start

2019-03-25

Primary completion

2020-02-27

Completion

2020-02-27

Outcome

Outcome not reported

Stopped: “MOR106 clinical development in atopic dermatitis was stopped for futility”

Drugs

Indications